{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:25:41Z","timestamp":1792211141698,"version":"4.4.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T00:00:00Z","timestamp":1568073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","award":["DS 352"],"award-info":[{"award-number":["DS 352"]}],"id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Amphotericin B (AmB) is a very potent antifungal drug with very rare resistance among clinical isolates. Treatment with the AmB formulations available currently is associated with severe side effects. A promising strategy to minimize the toxicity of AmB is reducing its dose by combination therapy with other antifungals, showing synergistic interactions. Therefore, substances that display synergistic interactions with AmB are still being searched for. Screening tests carried out on several dozen of synthetic 1,3,4-thiadiazole derivatives allowed selection of a compound called 4-(5-methyl-1,3,4-thiadiazole-2-yl) benzene-1,3-diol (abbreviated as C1), which shows strong synergistic interaction with AmB and low toxicity towards human cells. The aim of the present study was to investigate the type of <jats:italic>in vitro<\/jats:italic> antifungal interactions of the C1 compound with AmB against fungal clinical isolates differing in susceptibility. The results presented in the present paper indicate that the C1 derivative shows strong synergistic interaction with AmB, which allows the use of a dozen to several dozen times lower AmB concentration necessary for 100% inhibition of the growth of pathogenic fungi <jats:italic>in vitro<\/jats:italic>. Synergistic interactions were noted for all tested strains, including strains with reduced sensitivity to AmB and azole-resistant isolates. These observations give hope for the possibility of application of the AmB - C1 combinatory therapy in the treatment of fungal infections.<\/jats:p>","DOI":"10.1038\/s41598-019-49425-1","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T10:04:12Z","timestamp":1568109852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Synergistic antifungal interactions of amphotericin B with 4-(5-methyl-1,3,4-thiadiazole-2-yl) benzene-1,3-diol"],"prefix":"10.1038","volume":"9","author":[{"given":"Barbara","family":"Chudzik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Bonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0449-2375","authenticated-orcid":false,"given":"Wojciech","family":"Dabrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pietrzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Niewiadomy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Olender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Malodobry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Gago\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,10]]},"reference":[{"key":"49425_CR1","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S0140-6736(02)08162-X","volume":"359","author":"DP Kontoyiannis","year":"2002","unstructured":"Kontoyiannis, D. P. & Lewis, R. E. Antifungal drug resistance of pathogenic fungi. Lancet 359, 1135\u20131144 (2002).","journal-title":"Lancet"},{"key":"49425_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1586\/eri.09.67","volume":"7","author":"MT Fera","year":"2009","unstructured":"Fera, M. T., La Camera, E. & De Sarro, A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti-Infe 7, 981\u2013998 (2009).","journal-title":"Expert Rev Anti-Infe"},{"key":"49425_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/tcrm.2007.3.1.71","volume":"3","author":"G Eschenauer","year":"2007","unstructured":"Eschenauer, G., Depestel, D. D. & Carver, P. L. Comparison of echinocandin antifungals. Ther Clin Risk Manag 3, 71\u201397 (2007).","journal-title":"Ther Clin Risk Manag"},{"key":"49425_CR4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fmicb.2012.00286","volume":"3","author":"AC Mesa-Arango","year":"2012","unstructured":"Mesa-Arango, A. C., Scorzoni, L. & Zaragoza, O. It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug. Front Microbiol 3, 286 (2012).","journal-title":"Front Microbiol"},{"key":"49425_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0005-2736(02)00581-3","volume":"1567","author":"M Baginski","year":"2002","unstructured":"Baginski, M., Resat, H. & Borowski, E. Comparative molecular dynamics simulations of amphotericin B-cholesterol\/ergosterol membrane channels. Bba-Biomembranes 1567, 63\u201378 (2002).","journal-title":"Bba-Biomembranes"},{"key":"49425_CR6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00232-009-9187-z","volume":"230","author":"EA Romero","year":"2009","unstructured":"Romero, E. A., Valdivieso, E. & Cohen, B. E. Formation of Two Different Types of Ion Channels by Amphotericin B in Human Erythrocyte Membranes. J Membrane Biol 230, 69\u201381 (2009).","journal-title":"J Membrane Biol"},{"key":"49425_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00232-010-9313-y","volume":"238","author":"BE Cohen","year":"2010","unstructured":"Cohen, B. E. Amphotericin B Membrane Action: Role for Two Types of Ion Channels in Eliciting Cell Survival and Lethal Effects. J Membrane Biol 238, 1\u201320 (2010).","journal-title":"J Membrane Biol"},{"key":"49425_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13181-010-0120-8","volume":"7","author":"GP Patel","year":"2011","unstructured":"Patel, G. P., Crank, C. W. & Leikin, J. B. An evaluation of hepatotoxicity and nephrotoxicity of liposomal amphotericin B (L-AMB). J Med Toxicol 7, 12\u201315 (2011).","journal-title":"J Med Toxicol"},{"key":"49425_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/02652049809006844","volume":"15","author":"M Gulati","year":"1998","unstructured":"Gulati, M., Bajad, S., Singh, S., Ferdous, A. J. & Singh, M. Development of liposomal amphotericin B formulation. J Microencapsul 15, 137\u2013151 (1998).","journal-title":"J Microencapsul"},{"key":"49425_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/13693780701730469","volume":"46","author":"F Saliba","year":"2008","unstructured":"Saliba, F. & Dupont, B. Renal impairment and Amphotericin B formulations in patients with invasive fungal infections. Medical Mycology 46, 97\u2013112 (2008).","journal-title":"Medical Mycology"},{"key":"49425_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s00253-005-1955-9","volume":"68","author":"A Lemke","year":"2005","unstructured":"Lemke, A., Kiderlen, A., Kayser, O. & Amphotericin, B. Appl Microbiol Biot 68, 151\u2013162 (2005).","journal-title":"Appl Microbiol Biot"},{"key":"49425_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0006-2952(88)90168-2","volume":"37","author":"M Cheron","year":"1988","unstructured":"Cheron, M. et al. Quantitative Structure Activity Relationships in Amphotericin-B Derivatives. Biochem Pharmacol 37, 827\u2013836 (1988).","journal-title":"Biochem Pharmacol"},{"key":"49425_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s10534-011-9445-2","volume":"24","author":"M Gagos","year":"2011","unstructured":"Gagos, M., Czernel, G., Kaminski, D. M. & Kostro, K. Spectroscopic studies of amphotericin B-Cu2+ complexes. Biometals 24, 915\u2013922 (2011).","journal-title":"Biometals"},{"key":"49425_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ejps.2013.06.007","volume":"49","author":"B Chudzik","year":"2013","unstructured":"Chudzik, B. et al. Amphotericin B-copper(II) complex as a potential agent with higher antifungal activity against Candida albicans. Eur J Pharm Sci 49, 850\u2013857 (2013).","journal-title":"Eur J Pharm Sci"},{"key":"49425_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","volume":"368","author":"JN Day","year":"2013","unstructured":"Day, J. N. et al. Combination Antifungal Therapy for Cryptococcal Meningitis. New Engl J Med 368, 1291\u20131302 (2013).","journal-title":"New Engl J Med"},{"key":"49425_CR16","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1128\/AAC.46.10.3208-3214.2002","volume":"46","author":"RE Lewis","year":"2002","unstructured":"Lewis, R. E., Prince, R. A., Chi, J. D. & Kontoyiannis, D. P. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Ch 46, 3208\u20133214 (2002).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1128\/AAC.39.9.1907","volume":"39","author":"AM Sugar","year":"1995","unstructured":"Sugar, A. M. Use of Amphotericin-B with Azole Antifungal. Drugs - What Are We Doing. Antimicrob Agents Ch 39, 1907\u20131912 (1995).","journal-title":"Drugs - What Are We Doing. Antimicrob Agents Ch"},{"key":"49425_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1128\/AAC.39.3.598","volume":"39","author":"AM Sugar","year":"1995","unstructured":"Sugar, A. M., Hitchcock, C. A., Troke, P. F. & Picard, M. Combination Therapy of Murine Invasive Candidiasis with Fluconazole and Amphotericin-B. Antimicrob Agents Ch 39, 598\u2013601 (1995).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR19","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/jac\/dkh434","volume":"54","author":"M Cuenca-Estrella","year":"2004","unstructured":"Cuenca-Estrella, M. Combinations of antifungal agents in therapy - what value are they? J Antimicrob Chemoth 54, 854\u2013869 (2004).","journal-title":"J Antimicrob Chemoth"},{"key":"49425_CR20","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1128\/AAC.06098-11","volume":"56","author":"JRA Santos","year":"2012","unstructured":"Santos, J. R. A. et al. Dynamic Interaction between Fluconazole and Amphotericin B against Cryptococcus gattii. Antimicrob Agents Ch 56, 2553\u20132558 (2012).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1128\/AAC.45.2.485-494.2001","volume":"45","author":"A Louie","year":"2001","unstructured":"Louie, A. et al. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Ch 45, 485\u2013494 (2001).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR22","doi-asserted-by":"publisher","first-page":"S188","DOI":"10.1086\/376524","volume":"37","author":"WJ Steinbach","year":"2003","unstructured":"Steinbach, W. J., Stevens, D. A. & Denning, D. W. Combination and sequential antifungal therapy for invasive aspergillosis: Review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 37, S188\u2013S224 (2003).","journal-title":"Clin Infect Dis"},{"key":"49425_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1128\/AAC.41.6.1345","volume":"41","author":"H Sanati","year":"1997","unstructured":"Sanati, H., Ramos, C. F., Bayer, A. S. & Ghannoum, M. A. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models. Antimicrob Agents Ch 41, 1345\u20131348 (1997).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR24","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1128\/AAC.48.6.2007-2013.2004","volume":"48","author":"DTAT Dorsthorst","year":"2004","unstructured":"Dorsthorst, D. T. A. T., Verweij, P. E., Meis, J. F. G. M., Punt, N. C. & Mouton, J. W. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob Agents Ch 48, 2007\u20132013 (2004).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR25","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1128\/AAC.35.8.1669","volume":"35","author":"AM Sugar","year":"1991","unstructured":"Sugar, A. M. Interactions of Amphotericin-B and Sch-39304 in the Treatment of Experimental Murine Candidiasis - Lack of Antagonism of a Polyene-Azole Combination. Antimicrob Agents Ch 35, 1669\u20131671 (1991).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1128\/AAC.38.2.371","volume":"38","author":"AM Sugar","year":"1994","unstructured":"Sugar, A. M., Salibian, M. & Goldani, L. Z. Saperconazole Therapy of Murine Disseminated Candidiasis - Efficacy and Interactions with Amphotericin-B. Antimicrob Agents Ch 38, 371\u2013373 (1994).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR27","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1128\/AAC.35.9.1721","volume":"35","author":"MM Albert","year":"1991","unstructured":"Albert, M. M., Graybill, J. R. & Rinaldi, M. G. Treatment of Murine Cryptococcal Meningitis with an Sch-39304-Amphotericin-B Combination. Antimicrob Agents Ch 35, 1721\u20131725 (1991).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1086\/374856","volume":"36","author":"FC Odds","year":"2003","unstructured":"Odds, F. C. Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia. Clin Infect Dis 36, 1229\u20131231 (2003).","journal-title":"Clin Infect Dis"},{"key":"49425_CR29","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1128\/AAC.35.10.2128","volume":"35","author":"AM Sugar","year":"1991","unstructured":"Sugar, A. M., Goldani, L. Z. & Picard, M. Treatment of Murine Invasive Candidiasis with Amphotericin-B and Cilofungin - Evidence for Enhanced Activity with Combination Therapy. Antimicrob Agents Ch 35, 2128\u20132130 (1991).","journal-title":"Antimicrob Agents Ch"},{"key":"49425_CR30","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ijantimicag.2016.07.025","volume":"48","author":"F Sangalli-Leite","year":"2016","unstructured":"Sangalli-Leite, F. et al. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation. Int J Antimicrob Ag 48, 504\u2013511 (2016).","journal-title":"Int J Antimicrob Ag"},{"key":"49425_CR31","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/ptr.5650","volume":"30","author":"STS Hassan","year":"2016","unstructured":"Hassan, S. T. S., Berchova-Bimova, K. & Petras, J. Plumbagin, a Plant-Derived Compound, Exhibits Antifungal Combinatory Effect with Amphotericin B against Candida albicans Clinical Isolates and Anti-hepatitis C Virus Activity. Phytother Res 30, 1487\u20131492 (2016).","journal-title":"Phytother Res"},{"key":"49425_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41429-018-0128-x","volume":"72","author":"R Uchida","year":"2019","unstructured":"Uchida, R. et al. Simpotentin, a new potentiator of amphotericin B activity against Candida albicans, produced by Simplicillium minatense FKI-4981. J Antibiot 72, 134\u2013140 (2019).","journal-title":"J Antibiot"},{"key":"49425_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/cbdd.12125","volume":"81","author":"AK Jain","year":"2013","unstructured":"Jain, A. K., Sharma, S., Vaidya, A., Ravichandran, V. & Agrawal, R. K. 1,3,4-Thiadiazole and its Derivatives: A Review on Recent Progress in Biological Activities. Chem Biol Drug Des 81, 557\u2013576 (2013).","journal-title":"Chem Biol Drug Des"},{"key":"49425_CR34","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2147\/DDDT.S155958","volume":"12","author":"G Serban","year":"2018","unstructured":"Serban, G., Stanasel, O., Serban, E. & Bota, S. 2-Amino-1,3,4-thiadiazole as a potential scaffold for promising antimicrobial agents. Drug Des Dev Ther 12, 1545\u20131566 (2018).","journal-title":"Drug Des Dev Ther"},{"key":"49425_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/hc.20645","volume":"21","author":"J Matysiak","year":"2010","unstructured":"Matysiak, J., Skrzypek, A. & Niewiadomy, A. Synthesis and Antifungal Activity of Novel 5-Substituted 4-(1,3,4-Thiadiazol-2-yl) benzene-1,3-Diols. Heteroatom Chem 21, 533\u2013540 (2010).","journal-title":"Heteroatom Chem"},{"key":"49425_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jhet.5570430108","volume":"43","author":"J Matysiak","year":"2006","unstructured":"Matysiak, J. Synthesis of 5-substituted 2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. J Heterocyclic Chem 43, 55\u201358 (2006).","journal-title":"J Heterocyclic Chem"},{"key":"49425_CR37","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ejmech.2005.12.007","volume":"41","author":"J Matysiak","year":"2006","unstructured":"Matysiak, J. et al. Synthesis and antiproliferative activity of some 5-substituted 2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles. Eur J Med Chem 41, 475\u2013482 (2006).","journal-title":"Eur J Med Chem"},{"key":"49425_CR38","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1016\/j.bmcl.2012.07.036","volume":"22","author":"M Juszczak","year":"2012","unstructured":"Juszczak, M. et al. 2-Amino-1,3,4-thiadiazole derivative (FABT) inhibits the extracellular signal-regulated kinase pathway and induces cell cycle arrest in human non-small lung carcinoma cells. Bioorg Med Chem Lett 22, 5466\u20135469 (2012).","journal-title":"Bioorg Med Chem Lett"},{"key":"49425_CR39","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1016\/j.bmc.2007.02.041","volume":"15","author":"W Rzeski","year":"2007","unstructured":"Rzeski, W., Matysiak, J. & Kandefer-Szerszen, M. Anticancer, neuroprotective activities and computational studies of 2-amino-1,3,4-thiadiazole based compound. Bioorgan Med Chem 15, 3201\u20133207 (2007).","journal-title":"Bioorgan Med Chem"},{"key":"49425_CR40","doi-asserted-by":"publisher","first-page":"12047","DOI":"10.1021\/acs.jpcb.6b09371","volume":"120","author":"D Kluczyk","year":"2016","unstructured":"Kluczyk, D. et al. Molecular Organization of Dipalmitoylphosphatidylcholine Bilayers Containing Bioactive Compounds 4-(5-Heptyl-1,3,4-thiadiazol-2-yl) Benzene-1,3-diol and 4-(5-Methyl-1,3,4-thiadiazol-2-yl) Benzene-1,3-diols. J Phys Chem B 120, 12047\u201312063 (2016).","journal-title":"J Phys Chem B"},{"key":"49425_CR41","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1134\/S1068162007060106","volume":"33","author":"J Matysiak","year":"2007","unstructured":"Matysiak, J. & Malinski, Z. 2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazole analogues: Antifungal activity in vitro against Candida species. Russ J Bioorg Chem 33, 594\u2013601 (2007).","journal-title":"Russ J Bioorg Chem"},{"key":"49425_CR42","unstructured":"CLSI Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA (2008a)."},{"key":"49425_CR43","unstructured":"CLSI Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA (2008b)."},{"key":"49425_CR44","first-page":"331","volume":"47","author":"WR Greco","year":"1995","unstructured":"Greco, W. R., Bravo, G. & Parsons, J. C. The Search for Synergy - a Critical-Review from a Response-Surface Perspective. Pharmacol Rev 47, 331\u2013385 (1995).","journal-title":"Pharmacol Rev"},{"key":"49425_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemoth 52, 1\u20131 (2003).","journal-title":"J Antimicrob Chemoth"},{"key":"49425_CR46","unstructured":"Isenberg, H. D. E. Clinical Microbiology Procedures Handbook. American Society for Microbiology, Washington DC. (1992)."},{"key":"49425_CR47","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4161\/auto.8.2.18600","volume":"8","author":"K Singh","year":"2012","unstructured":"Singh, K., Matsuyama, S., Drazba, J. A. & Almasan, A. Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy 8, 236\u2013251 (2012).","journal-title":"Autophagy"},{"key":"49425_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0091-679X(08)61717-3","volume":"41","author":"F Traganos","year":"1994","unstructured":"Traganos, F. & Darzynkiewicz, Z. Lysosomal Proton Pump Activity - Supravital Cell Staining with Acridine-Orange Differentiates Leukocyte Subpopulations. Method Cell Biol 41, 185\u2013194 (1994).","journal-title":"Method Cell Biol"},{"key":"49425_CR49","first-page":"1297","volume":"29","author":"W Jakubowski","year":"1997","unstructured":"Jakubowski, W. & Bartosz, G. Estimation of oxidative stress in Saccharomyces cerevisiae with fluorescent probes. Int J Biochem. Cell B 29, 1297\u20131301 (1997).","journal-title":"Cell B"},{"key":"49425_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejps.2016.10.040","volume":"97","author":"B Chudzik","year":"2017","unstructured":"Chudzik, B., Czernel, G., Miaskowski, A. & Gagos, M. Amphotericin B-copper(II) complex shows improved therapeutic index in vitro. Eur J Pharm Sci 97, 9\u201321 (2017).","journal-title":"Eur J Pharm Sci"},{"key":"49425_CR51","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ajt.12118","volume":"13","author":"S Huprikar","year":"2013","unstructured":"Huprikar, S. & Shoham, S. & Practice, A.I.D.C. Emerging Fungal Infections in Solid Organ Transplantation. Am J Transplant 13, 262\u2013271 (2013).","journal-title":"Am J Transplant"},{"key":"49425_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/MAJ.0b013e3181e99c88","volume":"340","author":"PG Pappas","year":"2010","unstructured":"Pappas, P. G. Opportunistic Fungi: A View to the Future. Am J Med Sci 340, 253\u2013257 (2010).","journal-title":"Am J Med Sci"},{"key":"49425_CR53","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1110404","volume":"368","author":"JN Day","year":"2013","unstructured":"Day, J. N., Chau, T. T. & Lalloo, D. G. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 368, 2522\u20132523 (2013).","journal-title":"N Engl J Med"},{"key":"49425_CR54","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1128\/AAC.39.9.1907","volume":"39","author":"AM Sugar","year":"1995","unstructured":"Sugar, A. M. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 39, 1907\u20131912 (1995).","journal-title":"Antimicrob Agents Chemother"},{"key":"49425_CR55","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1128\/AAC.06098-11","volume":"56","author":"JR Santos","year":"2012","unstructured":"Santos, J. R. et al. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. Antimicrob Agents Chemother 56, 2553\u20132558 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"49425_CR56","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1128\/AAC.48.6.2007-2013.2004","volume":"48","author":"DT Te Dorsthorst","year":"2004","unstructured":"Te Dorsthorst, D. T., Verweij, P. E., Meis, J. F., Punt, N. C. & Mouton, J. W. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob Agents Chemother 48, 2007\u20132013 (2004).","journal-title":"Antimicrob Agents Chemother"},{"key":"49425_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00249-014-1003-8","volume":"44","author":"B Chudzik","year":"2015","unstructured":"Chudzik, B., Koselski, M., Czurylo, A., Trebacz, K. & Gagos, M. A new look at the antibiotic amphotericin B effect on Candida albicans plasma membrane permeability and cell viability functions. Eur Biophys J Biophy 44, 77\u201390 (2015).","journal-title":"Eur Biophys J Biophy"},{"key":"49425_CR58","doi-asserted-by":"publisher","first-page":"14327","DOI":"10.1073\/pnas.2332326100","volume":"100","author":"AJ Phillips","year":"2003","unstructured":"Phillips, A. J., Sudbery, I. & Ramsdale, M. Apoptosis induced by environmental stresses and amphotericin B in Candida albicans. P Natl Acad Sci USA 100, 14327\u201314332 (2003).","journal-title":"P Natl Acad Sci USA"},{"key":"49425_CR59","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1073\/pnas.1117280109","volume":"109","author":"KC Gray","year":"2012","unstructured":"Gray, K. C. et al. Amphotericin primarily kills yeast by simply binding ergosterol. P Natl Acad Sci USA 109, 2234\u20132239 (2012).","journal-title":"P Natl Acad Sci USA"},{"key":"49425_CR60","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1128\/AAC.34.2.183","volume":"34","author":"J Brajtburg","year":"1990","unstructured":"Brajtburg, J., Powderly, W. G., Kobayashi, G. S. & Medoff, G. Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 34, 183\u2013188 (1990).","journal-title":"Antimicrob Agents Chemother"},{"key":"49425_CR61","doi-asserted-by":"publisher","first-page":"14327","DOI":"10.1073\/pnas.2332326100","volume":"100","author":"AJ Philips","year":"2003","unstructured":"Philips, A. J., Sudbery, I. & Ramsdale, M. Apoptosis induced by environmental stress and amphotericin B in Candida albicans. PNAS 100, 14327\u201314332 (2003).","journal-title":"PNAS"},{"key":"49425_CR62","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.micinf.2011.01.015","volume":"13","author":"F Sangalli-Leite","year":"2011","unstructured":"Sangalli-Leite, F. et al. Amphotericin B mediates killing in Cryptococcus neoformans through the induction of a strong oxidative burst. Microbes Infect 13, 457\u2013467 (2011).","journal-title":"Microbes Infect"},{"key":"49425_CR63","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/infdis\/154.1.76","volume":"154","author":"ML Sokol-Anderson","year":"1986","unstructured":"Sokol-Anderson, M. L., Brajtburg, J. & Medoff, G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis 154, 76\u201383 (1986).","journal-title":"J Infect Dis"},{"key":"49425_CR64","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1099\/jmm.0.015784-0","volume":"59","author":"RS Al-Dhaheri","year":"2010","unstructured":"Al-Dhaheri, R. S. & Douglas, L. J. Apoptosis in Candida biofilms exposed to amphotericin B. J Med Microbiol 59, 149\u2013157 (2010).","journal-title":"J Med Microbiol"},{"key":"49425_CR65","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1099\/mic.0.26830-0","volume":"150","author":"SA Mousavi","year":"2004","unstructured":"Mousavi, S. A. & Robson, G. D. Oxidative and amphotericin B-mediated cell death in the opportunistic pathogen Aspergillus fumigatus is associated with an apoptotic-like phenotype. Microbiology 150, 1937\u20131945 (2004).","journal-title":"Microbiology"},{"key":"49425_CR66","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1023\/B:MYCO.0000038430.20669.80","volume":"158","author":"Y Okamoto","year":"2004","unstructured":"Okamoto, Y., Aoki, S. & Mataga, I. Enhancement of amphotericin B activity against Candida albicans by superoxide radical. Mycopathologia 158, 9\u201315 (2004).","journal-title":"Mycopathologia"},{"key":"49425_CR67","first-page":"570","volume":"10","author":"M Sharma","year":"2010","unstructured":"Sharma, M., Manoharlal, R., Negi, A. S. & Prasad, R. Synergistic anticandidal activity of pure polyphenol curcumin I in combination with azoles and polyenes generates reactive oxygen species leading to apoptosis. FEMS Yeast Res 10, 570\u2013578 (2010).","journal-title":"FEMS Yeast Res"},{"key":"49425_CR68","doi-asserted-by":"crossref","unstructured":"Gil-Bona, A. et al. The Cell Wall Protein Ecm33 of Candida albicans is Involved in Chronological Life Span, Morphogenesis, Cell Wall Regeneration, Stress Tolerance, and Host-Cell Interaction. Front Microbiol 7 (2016).","DOI":"10.3389\/fmicb.2016.00064"},{"key":"49425_CR69","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1128\/EC.5.1.140-147.2006","volume":"5","author":"R Martinez-Lopez","year":"2006","unstructured":"Martinez-Lopez, R., Park, H., Myers, C. L., Gil, C. & Filler, S. G. Candida albicans Ecm33p is important for normal cell wall architecture and interactions with host cells. Eukaryot Cell 5, 140\u2013147 (2006).","journal-title":"Eukaryot Cell"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49425-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49425-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T13:24:57Z","timestamp":1671283497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-49425-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,10]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["49425"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-49425-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,10]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12945"}}